A Phase I Study Evaluating the Safety of Stereotactic Central Ablative Radiation Therapy (SCART) for Bulky Metastatic or Recurrent Cancer

Inclusion Criteria:

3.1.1 Patients must have a history of histologically confirmed metastatic or recurrent cancers.

3.1.2 Patients must have measurable disease documented by CT and/or PET that is amenable for SCART radiation with the shortest axis of 3 cm or longer.

3.1.3 Patients must be 18 years of age or older, as this is not a pediatric protocol. There is no maximum age restriction.

3.1.4 Patients must have a life expectancy of at least 6 months in order for the study endpoints to be evaluable.

3.1.5 Patients must have a Zubrod/GOG performance status of 0 or 1.

3.1.6 Patients must have normal organ and marrow function as defined below: leukocyte\>3,000/m l absolute neutrophil count \>1,500/m l platelets \>100,000/m l bilirubin within normal institutional limits AST(SGOT)/ALT(SGPT) 2.5 X institutional upper limit of normal Creatinine within normal institutional limits OR; Creatinine clearance \> 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.

3.1.7 Women of child-bearing potential will be asked to use adequate contraception.

3.1.8 Patients must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

3.2.1 Women who are pregnant or breastfeeding will be excluded.

3.2.2 Patients must not have any co-morbidity with life expectancy ≤ 6 months, or any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

3.2.3 Patients must not have active Crohn's disease or inflammatory bowel disease (IBD).

\-